Abstract: The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Abstract: A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.

Abstract: The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Abstract: A composition may be used in vascular relaxation, wherein the composition may include one or more anthocyanins.

Abstract: A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.

Abstract: A composition may be used as antioxidant, wherein the composition includes one or more of the following anthocyanins: cyanidin-3-glucoside, cyanidin-3-rutinoside, delphinidin-3-glucoside, malvidin-3-galactoside, petunidin-3-galactoside, and/or malvidin-3-glucoside.

Abstract: The present invention relates to a system for monitoring physiological parameters to an integrated digital system, which is able to determine several biological parameters, such as from photoplethysmographic (PPG) signals and other connected devices or sensors to give a personalized supplement, nutritional and lifestyle recommendation to improve specifically said parameters. By using new algorithms based on PPG signals the cardiovascular condition of a person can be analyzed by estimating cardiovascular parameters.

Abstract: The present invention is related to preparations containing one or more anthocyanins for use in the prevention and treatment of cardiovascular diseases and reduction of arterial stiffness in a subject.

Abstract: The present invention relates to a method to estimate the blood pressure and the arterial stiffness based on photoplethysmographic (PPG) signals. New algorithms have been developed and validated based on PPG signals to analyze the cardiovascular condition of a person by estimating cardiovascular parameters. With the present invention a method for measuring one or more cardiovascular parameters in a subject based on PPG signals is provided.

Abstract: The present invention is directed to biocompatible polymeric powders to be used for 3D printing applications. More specifically, the 3D printing process will allow a tool less manufacturing of medical devices in particular in the implantables or regenerative space. Its flow and other processing characteristics qualifies them for the use in selective laser sintering, but also could be suitable for other powder based 3D printing technologies.

Abstract: A method can estimate the blood pressure and the arterial stiffness based on photoplethysmographic (PPG) signals. Algorithms can be based on PPG signals to analyze the cardiovascular condition of a person by estimating cardiovascular parameters. A method can measure one or more cardiovascular parameters in a subject based on PPG signals.

Abstract: Composite materials comprising thermoplastic polymeric material such as polyaryletherketones (PAEKs) and inorganic additive species serving to increase the processing and resultant mechanical, thermal, and biological properties of said thermoplastic polymeric material which may be subsequently used in various medical applications after the two materials are mixed through thermal processing methods. The inorganic additive species may be a calcium salt, and may include fluorine ions.

Abstract: The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.

Abstract: The invention provides a gastric resistant, enteric-coated solid dosage form including a core containing a pharmaceutically active ingredient, an inner coating for the core, and an outer enteric coating. The inner coating comprises an anionic polymeric material or a water-soluble neutral polymeric material, and further comprises a water soluble inorganic salt which is not a carbonate or bicarbonates. The outer enteric coating comprises an anionic polymeric material which is less neutralized than the polymeric material comprising the inner coating and disintegrates rapidly at a pH of 5.5 to 7.0 upon entering the small intestine.

Abstract: A process for preparing poly(lactide-co-glycolide) copolymer particles with an average particle size in the range of 50-800 nm includes transferring a mixture of poly(lactide-co-glycolide) copolymer, ethanol and carbon dioxide from a first reactor into a second reactor under rapid reduction of the pressure and expansion with phase separation into a gas phase, an ethanol aerosol and an ethanolic suspension containing poly(lactide-co-glycolide) copolymer particles, removing the carbon dioxide gas and the ethanol aerosol from the second reactor, and obtaining the poly(glycolide-co-lactide) copolymer particles in the form of an ethanolic suspension or in dry form from the second reactor.

Abstract: The invention refers to a nanoparticle with a diameter which is the maximum in the nanoparticle size distribution, in the range of 10-300 nm, comprising a) a calcium phosphate nanoparticle core a), b) an active ingredient coating b) on the calcium phosphate nanoparticle core a), c) a lactic acid polymer coating c) on the active ingredient coating b), d) a cationic polymer coating d) on the lactic acid polymer coating c) selected from the group of polyethylene-imines, chitosan and human lactoferrin-derived peptides with a length of 14 to 30 amino acids.

Abstract: A process for preparing poly(lactide-co-glycolide) copolymer particles with an average particle size in the range of 50-800 nm includes transferring a mixture of poly(lactide-co-glycolide) copolymer, ethanol and carbon dioxide from a first reactor into a second reactor under rapid reduction of the pressure and expansion with phase separation into a gas phase, an ethanol aerosol and an ethanolic suspension containing poly(lactide-co-glycolide) copolymer particles, removing the carbon dioxide gas and the ethanol aerosol from the second reactor, and obtaining the poly(glycolide-co-lactide) copolymer particles in the form of an ethanolic suspension or in dry form from the second reactor.

Abstract: The invention refers to a nanoparticle with a diameter which is the maximum in the nanoparticle size distribution, in the range of 10-300 nm, comprising a) a calcium phosphate nanoparticle core a), b) an active ingredient coating b) on the calcium phosphate nanoparticle core a), c) a lactic acid polymer coating c) on the active ingredient coating b), d) a cationic polymer coating d) on the lactic acid polymer coating c) selected from the group of polyethylene-imines, chitosan and human lactoferrin-derived peptides with a length of 14 to 30 amino acids.

Abstract: The present invention provides a solid dosage form including an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein the inner coating includes a partially neutralized anionic polymeric material, and at least a carboxylic acid having 2 to 16 carbon atoms the salts thereof or mixtures of the acid and its salt; wherein the outer coating includes an anionic polymeric material which is less or not at all neutralized than the material of the inner coating.

Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.